03 October 2020 22:32

Trump Donald Trump Donald Trump

Trump at Walter Reed: President receives experimental drug Regeneron; Cook County Health also testing the possible coronavirus treatment

President Donald Trump, who recently tested positive for the coronavirus, has been given a dose of Gilead Sciences Inc.'s remdesivir in addition to Regeneron Pharmaceuticals Inc.'s experimental neutralizing antibody cocktail. Both treatments have received emergency use authorization from the Food and Drug Administration based on clinical data evaluating their effectiveness in hospitalized patients with more severe forms of the disease. Dr. Sean Conley, Trump's physician, said Saturday morning during a news conference that Trump was diagnosed 72 hours ago, which would be Wednesday morning — about 36 hours before he disclosed his diagnosis. Conley said Friday evening that Trump had received an infusion of Regeneron's REGN, -0.58% REGN-COV2. Conley said Saturday morning that Trump had received the drug "48 hours ago," which would Thursday morning.

Conely said Saturday morning that Trump has been started on a five-day regimen of Gilead's GILD, -1.81% remdesivir and does not currently require supplemental oxygen. For people with severe forms of the disease, treatment can include convalescent plasma, the steroid dexamethasone, and/or remdesivir. For people with mild to moderate forms of the disease, there are no authorized or approved drugs, though two drug makers recently shared promising results for a pair of still-investigational antibody-based treatments. "There really aren't a lot of very effective therapies we have at this stage of the disease," said Dr. Steven Shapiro, chief medical and scientific officer at UPMC, a hospital system based in Pittsburgh. The first drug, Regeneron's REGN-COV2, that Trump received is being studied as a treatment for people with mild to moderate forms of the disease.

Like convalescent-plasma treatments, these drugs also use antibodies, and both have shown so far that they help reduce viral load, based on interim data shared in the past month. Most of the available treatments for COVID-19 infections target severely ill patients who have been hospitalized. This includes Gilead's remdesivir and convalescent plasma, which is gathered from people who have recovered from COVID-19 infections. The steroid, which is approved by the FDA for other indications, demonstrated in clinical trials in the U.K. that it can reduce mortality in some severely ill COVID-19 patients. That said, physicians have the discretion to prescribe medications that are not approved or authorized by the FDA for a specific use.

At that time it was being tested in clinical trials as both a treatment and to see if it could prevent infections in people who had been exposed to the virus. Health-care providers around the world have tested the efficacy of providing zinc, vitamin C, vitamin D and the antibiotic azithromycin to COVID-19 patients; however, none of those treatments has so far shown a clinical benefit, according to Shapiro. President Trump's physician is treating his coronavirus diagnosis with Regeneron's experimental treatment and his one infusion "seemed to go through very well" and "will last a long time," the company's chief scientific officer explained to "CAVUTO Live" Saturday. REGENERON IS TRUMP'S COVID-19 TREATMENT: WHAT TO KNOW "It's all about beating the virus and so we're just helping the natural immune system beat it, by supplementing it with this antibody cocktail," Dr. George Yancopoulos, the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals, explained to host Neil Cavuto. With just one injection, like Trump had, based on the results the company released this week, it can last for months to treat and beat the virus but also protect the patient.

TRUMP TAKING REGENERON, REMDESIVIR THERAPY FOR CORONAVIRUS DIAGNOSIS: EX-WH DOCTOR EXPLAINS "We use this to produce some of the most important and safest medicines in the world right now, to fight blindness, asthma, cancer, atopic dermatitis, heart disease and most importantly, we used this to produce the first therapeutic that will be approved by the FDA for Ebola, and so we made an antibody cocktail specific for ebola. US President Donald Trump was given an experimental antibody drug after he tested positive for the coronavirus disease (Covid-19) on Thursday. He was given the drug at the White House after its maker Regeneron Pharmaceuticals Inc received a compassionate-use request from officials. * The experimental drug has been manufactured by Regeneron Pharmaceuticals Inc, which has developed a successful Ebola treatment from an antibody combo in the past. * It is a single-dose therapy and being tested in several clinical trials in both hospitalised Covid-19 patients and patients outside hospitals. * Monoclonal antibodies are considered one of the most promising potential treatments for Covid-19, and Regeneron is one of the front-runners in testing them. * Before this, Regeneron said the preliminary result showed that the drug may help treat coronavirus patients outside of the hospital by reducing virus levels and symptoms. EMBED>More News Videos Dr. Chris Colbert discussed President Donald Trump's COVID-19 treatment and the importance of flu shots Saturday morning. CHICAGO (WLS)--As part of his COVID-19 treatment, President Donald Trump received the experimental drug Regeneron Friday; Cook County Health is currently seeking volunteers to participate in its clinical trials for the same treatment option.Trump is waking up Saturday in the hospital out of what the White House is calling an "abundance of caution." He's at the Walter Reed Medical Center in Bethesda, Maryland. The White House said he was experiencing mild symptoms from COVID-19.He was taken to Walter Reed after suffering from a low-grade fever, chills, nasal congestion and a cough, multiple sources told ABC News.The president is being treated with remdesivir and an experimental antibody cocktail from Regeneron, which is also being tested at Cook County Hospital."The idea is what they attach to that spike protein and prevent the virus from being able to replicate in the system," said Sybil Hosek, a clinical psychologist and principal investigator at Cook County Health. And that's the case of the president; he's getting this as an early treatment, potential early treatment for prevention."Cook County Health is one of several major medical centers across the U.S. and the second site in Illinois to begin enrollment into the Phase III clinical trial, medical officials said. Cook County Health researchers are seeking asymptomatic, healthy adults who are close household contacts to an individual who has recently tested positive for COVID-19.The Regeneron clinical program consists of three separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients and uninfected people with close exposure to a COVID-19 patient or living with someone who has tested positive for COVID-19. Other visits will be conducted by home health care teams.For more information, visitCook county health's lead researcher on the Regeneron study said the antibody treatment is a temporary fix and cannot replace a vaccine. WASHINGTON (AFP) - President Donald Trump was treated Friday for Covid-19 with a high-dose of the experimental antibody drug developed by the US biotech firm Regeneron. What is it, how far along are its clinical trials, and why do some experts disagree with using a medicine before it's been approved? Regeneron's treatment, called REGN-COV2, is a combination or "cocktail" of two antibodies: infection-fighting proteins that were developed to bind to the part of the new coronavirus that it uses to invade human cells. Vaccines work by teaching the body to make its own antibodies, but scientists are also testing ready-made antibodies from convalescent plasma, taken from the blood of recovered patients. In a paper published in Science in June, Regeneron scientists described how they selected the two best antibodies from both recovered human patients and infected mice that were genetically modified to give them human-like immune systems. The company used the same "humanized mouse" technology to develop a triple-antibody cocktail which was shown to be effective against Ebola last year. "That's part of what's giving us confidence, the platform has been tried and has been shown to be to work very, very well," Christos Kyratsous, Regeneron's lead infectious disease scientist told AFP in March. On Tuesday, the firm announced some results from an early stage clinical trial, saying that its treatment reduced the viral load and recovery time in non-hospitalized Covid-19 patients. The results related to 275 patients, and Regeneron's president George Yancopoulos said the company had begun talks with regulatory authorities--presumably for temporary approval before full licensure. The company did not detail what these side-effects were, but Arun Swaminath, a doctor at New York's Lenox Hill Hospital, said that in general, mild reactions to IV-therapies include fevers, chills and fatigue. Regeneron is also running late-stage trials for hospitalized Covid-19 patients in the UK and for the drug's potential use to prevent household contacts of Covid-19 patients from being infected. The decision to give Trump the treatment before the trials have even produced enough data for emergency use authorization has puzzled some scientists.